Vertex Pharmaceuticals’ winning ways are being felt on Wall Street this morning. The Cambridge, MA-based drug developer’s (NASDAQ:[[ticker:VRTX]]) shock price was up 15 percent to $44:03 per share as of 10:14 am Eastern time today as investors reacted to positive results the firm revealed this morning from a late-stage trial of its treatment VX-770 for certain patients with cystic fibrosis. My colleague Luke Timmerman provided the details this morning of the game-changing study for certain patients with the genetic illness that causes thick mucus to build up in their lungs. The results follow the company’s impressive results from late-stage studies of its experimental treatment for hepatitis C infections, telaprevir. The company now has a market value of about $9 billion.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
